Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non Operating Income: 2012-2024

Historic Non Operating Income for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to -$15.7 million.

  • Amphastar Pharmaceuticals' Non Operating Income rose 59.35% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.3 million, marking a year-over-year increase of 32.22%. This contributed to the annual value of -$15.7 million for FY2024, which is 38.91% up from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Non Operating Income stood at -$15.7 million, which was up 38.91% from -$25.6 million recorded in FY2023.
  • Amphastar Pharmaceuticals' 5-year Non Operating Income high stood at $14.5 million for FY2021, and its period low was -$25.6 million during FY2023.
  • For the 3-year period, Amphastar Pharmaceuticals' Non Operating Income averaged around -$10.7 million, with its median value being -$15.7 million (2024).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Non Operating Income spiked by 320.74% in 2021, and later slumped by 382.62% in 2023.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Non Operating Income stood at -$6.6 million in 2020, then spiked by 320.74% to $14.5 million in 2021, then crashed by 37.62% to $9.1 million in 2022, then plummeted by 382.62% to -$25.6 million in 2023, then soared by 38.91% to -$15.7 million in 2024.